{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T02:48:56Z","timestamp":1793155736042,"version":"4.5.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100022896","name":"Australian and New Zealand Urogenital and Prostate Cancer Trials Group","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022896","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004324","name":"Astellas Pharma Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001111","name":"Cancer Australia","doi-asserted-by":"publisher","award":["1188642"],"award-info":[{"award-number":["1188642"]}],"id":[{"id":"10.13039\/501100001111","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004752","name":"State Government of Victoria","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004752","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1197190"],"award-info":[{"award-number":["1197190"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1196225"],"award-info":[{"award-number":["1196225"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["2009965"],"award-info":[{"award-number":["2009965"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["2016274"],"award-info":[{"award-number":["2016274"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.annonc.2025.05.529","type":"journal-article","created":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T11:06:49Z","timestamp":1747739209000},"page":"1068-1077","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Association of the circulating lipid panel, PCPro, with clinical outcomes in metastatic hormone-sensitive prostate cancer: post hoc analysis of the ENZAMET phase III randomised trial (ANZUP 1304)"],"prefix":"10.1016","volume":"36","author":[{"given":"H.-M.","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Scheinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Portman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.M.N.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Mellor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Huynh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.N.","family":"Faulkner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.A.","family":"Mellett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.D.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Joshua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"McJannett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Subhash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Yip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.A.","family":"Azad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.C.","family":"Marschner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.A.","family":"North","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.S.","family":"McDermott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.N.","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.R.","family":"Stockler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.J.","family":"Sweeney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.J.","family":"Meikle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.G.","family":"Horvath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.annonc.2025.05.529_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.annonc.2025.05.529_bib2","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1702900","article-title":"Abiraterone for prostate cancer not previously treated with hormone therapy","volume":"377","author":"James","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annonc.2025.05.529_bib3","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annonc.2025.05.529_bib4","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1056\/NEJMoa1903835","article-title":"Enzalutamide with standard first-line therapy in metastatic prostate cancer","volume":"381","author":"Davis","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annonc.2025.05.529_bib5","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S1470-2045(23)00063-3","article-title":"Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial","volume":"24","author":"Sweeney","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2025.05.529_bib6","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","article-title":"Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 \u00d7 2 factorial design","volume":"399","author":"Fizazi","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.annonc.2025.05.529_bib7","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","article-title":"Darolutamide and survival in metastatic, hormone-sensitive prostate cancer","volume":"386","author":"Smith","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annonc.2025.05.529_bib8","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/s41391-021-00338-z","article-title":"Aberrations in circulating ceramide levels are associated with poor clinical outcomes across localised and metastatic prostate cancer","volume":"24","author":"Lin","year":"2021","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.annonc.2025.05.529_bib9","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1002\/ijc.30903","article-title":"A distinct plasma lipid signature associated with poor prognosis in castration-resistant prostate cancer","volume":"141","author":"Lin","year":"2017","journal-title":"Int J Cancer"},{"key":"10.1016\/j.annonc.2025.05.529_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103625","article-title":"Overcoming enzalutamide resistance in metastatic prostate cancer by targeting sphingosine kinase","volume":"72","author":"Lin","year":"2021","journal-title":"EBioMedicine"},{"key":"10.1016\/j.annonc.2025.05.529_bib11","article-title":"Circulating lipid profiles associated with resistance to androgen deprivation therapy in localized prostate cancer","volume":"8","author":"Lin","year":"2024","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.annonc.2025.05.529_bib12","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/s41391-023-00666-2","article-title":"PCPro: a clinically accessible, circulating lipid biomarker signature for poor-prognosis metastatic prostate cancer","volume":"27","author":"Scheinberg","year":"2024","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.annonc.2025.05.529_bib13","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.chembiol.2018.10.008","article-title":"High-throughput plasma lipidomics: detailed mapping of the associations with cardiometabolic risk factors","volume":"26","author":"Huynh","year":"2019","journal-title":"Cell Chem Biol"},{"key":"10.1016\/j.annonc.2025.05.529_bib14","doi-asserted-by":"crossref","first-page":"3968","DOI":"10.1200\/JCO.2015.63.3651","article-title":"Biomarker: predictive or prognostic?","volume":"33","author":"Ballman","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annonc.2025.05.529_bib15","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.eururo.2018.02.001","article-title":"Burden of metastatic castrate naive prostate cancer patients, to identify men more likely to benefit from early docetaxel: further analyses of CHAARTED and GETUG-AFU15 studies","volume":"73","author":"Gravis","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.annonc.2025.05.529_bib16","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1093\/eurheartj\/ehz387","article-title":"Development and validation of a ceramide- and phospholipid-based cardiovascular risk estimation score for coronary artery disease patients","volume":"41","author":"Hilvo","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.annonc.2025.05.529_bib17","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.cmet.2021.06.006","article-title":"Sphingolipids in metabolic disease: the good, the bad, and the unknown","volume":"33","author":"Green","year":"2021","journal-title":"Cell Metab"},{"key":"10.1016\/j.annonc.2025.05.529_bib18","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1093\/eurheartj\/ehw148","article-title":"Plasma ceramides predict cardiovascular death in patients with stable coronary artery disease and acute coronary syndromes beyond LDL-cholesterol","volume":"37","author":"Laaksonen","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.annonc.2025.05.529_bib19","doi-asserted-by":"crossref","first-page":"E45","DOI":"10.1210\/jc.2013-2559","article-title":"Molecular lipids identify cardiovascular risk and are efficiently lowered by simvastatin and PCSK9 deficiency","volume":"99","author":"Tarasov","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.annonc.2025.05.529_bib20","doi-asserted-by":"crossref","first-page":"4792","DOI":"10.3390\/cancers14194792","article-title":"Modulation of plasma lipidomic profiles in metastatic castration-resistant prostate cancer by simvastatin","volume":"14","author":"Mak","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.annonc.2025.05.529_bib21","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/s41588-017-0026-3","article-title":"Compartmentalized activities of the pyruvate dehydrogenase complex sustain lipogenesis in prostate cancer","volume":"50","author":"Chen","year":"2018","journal-title":"Nat Genet"},{"key":"10.1016\/j.annonc.2025.05.529_bib22","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1038\/onc.2016.334","article-title":"Cell cycle-coupled expansion of AR activity promotes cancer progression","volume":"36","author":"McNair","year":"2017","journal-title":"Oncogene"},{"key":"10.1016\/j.annonc.2025.05.529_bib23","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s12916-022-02298-0","article-title":"Combined impact of lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancer","volume":"20","author":"Mak","year":"2022","journal-title":"BMC Med"},{"key":"10.1016\/j.annonc.2025.05.529_bib24","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/nrc.2017.96","article-title":"Sphingolipid metabolism in cancer signalling and therapy","volume":"18","author":"Ogretmen","year":"2018","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.annonc.2025.05.529_bib25","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/nature20792","article-title":"Genome-wide in vivo screen identifies novel host regulators of metastatic colonization","volume":"541","author":"van der Weyden","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.annonc.2025.05.529_bib26","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1002\/emmm.201200244","article-title":"Communication between host organism and cancer cells is transduced by systemic sphingosine kinase 1\/sphingosine 1-phosphate signalling to regulate tumour metastasis","volume":"4","author":"Ponnusamy","year":"2012","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.annonc.2025.05.529_bib27","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s00277-022-05056-7","article-title":"Phase I study of opaganib, an oral sphingosine kinase 2-specific inhibitor, in relapsed and\/or refractory multiple myeloma","volume":"102","author":"Kang","year":"2023","journal-title":"Ann Hematol"},{"key":"10.1016\/j.annonc.2025.05.529_bib28","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1158\/1078-0432.CCR-16-2363","article-title":"A phase I study of ABC294640, a first-in-class sphingosine kinase-2 inhibitor, in patients with advanced solid tumors","volume":"23","author":"Britten","year":"2017","journal-title":"Clin Cancer Res"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092375342500732X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092375342500732X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T03:00:41Z","timestamp":1788231641000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092375342500732X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":28,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S092375342500732X"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2025.05.529","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association of the circulating lipid panel, PCPro, with clinical outcomes in metastatic hormone-sensitive prostate cancer: post hoc analysis of the ENZAMET phase III randomised trial (ANZUP 1304)","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2025.05.529","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Society for Medical Oncology. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}